Abbott's spin-off AbbVie to join S&P 100 & 500
Dec 20 (Reuters) - AbbVie Inc, the pharmaceutical company being spun off by Abbott Laboratories, is set to join the Standard and Poor's 100 and 500 indices, S&P Dow Jones Indices said.
AbbVie will replace Dell Inc in the S&P 100 and Federated Investors Inc in the S&P 500.
Abbott Labs will remain in both indices.
DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.